Clinical Evidence on Tesamorelin and Changes in Visceral and Liver Fat

In a randomized clinical trial reported by Stanley et al. (2014), researchers evaluated the effects of the synthetic peptide tesamorelin, a growth hormone-releasing hormone analogue, on visceral adipose tissue (VAT) and liver fat in adults living with HIV who had abdominal fat accumulation. This study aimed to determine whether tesamorelin treatment could reduce not only visceral fat but also ectopic fat in the liver, a common concern in HIV-associated metabolic conditions.
According to the study design detailed by Stanley and colleagues, 50 HIV-infected adults with evidence of central obesity were randomized in a double-blind manner to receive either tesamorelin or placebo. Tesamorelin was administered daily for six months, and participants underwent imaging assessments — including computed tomography (CT) for visceral fat and magnetic resonance spectroscopy for liver fat — at baseline and after treatment to measure changes in tissue composition.
The results reported by the researchers indicated that, after six months of treatment, participants in the tesamorelin group experienced significant reductions in visceral adipose tissue compared with the placebo group. In addition, tesamorelin was associated with modest but statistically significant reductions in liver fat, as assessed by lipid-to-water percentage on spectroscopy, whereas the placebo group did not show similar decreases. These findings suggest that tesamorelin’s effects on fat distribution may extend beyond subcutaneous and visceral depots to include ectopic liver fat in this population.
Metabolic outcomes, such as fasting glucose and glucose tolerance, were also monitored, and the study noted transient increases in fasting glucose in the tesamorelin group early in treatment. However, by six months, differences between the tesamorelin and placebo groups in fasting glucose and 2-hour glucose were no longer statistically significant. Other measures related to insulin resistance and metabolic markers did not show clinically meaningful changes over the treatment period.
In their conclusions, Stanley et al. (2014) emphasized that tesamorelin administration for six months was associated with clinically measurable reductions in both visceral adipose tissue and liver fat in adults with HIV-associated abdominal obesity. The authors noted that while the magnitude of liver fat reduction was modest, these observations support the concept that targeted reduction of visceral adiposity may also influence ectopic fat deposits. They also highlighted the need for further research to determine the long-term clinical relevance of these changes, especially in relation to liver health outcomes and cardiometabolic risk.